Fixed-dose combination (antiretroviral)

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed-dose combinations are shown in the table below.

Brand Name Drug Names (INN) Date of FDA Approval Company
Combivir lamivudine + zidovudine September 26, 1997 GlaxoSmithKline
Kaletra lopinavir + ritonavir September 15, 2000 Abbott Laboratories
Trizivir abacavir + lamivudine + zidovudine November 15, 2000 GlaxoSmithKline
Epzicom (in USA)
Kivexa (in Europe and Russia)
abacavir + lamivudine August 2, 2004 GlaxoSmithKline
Truvada tenofovir + emtricitabine August 2, 2004 Gilead Sciences
Atripla emtricitabine + tenofovir + efavirenz July 12, 2006 Gilead Sciences and
Bristol-Myers Squibb
Complera (in USA)
Eviplera (in Europe and Russia)
emtricitabine + rilpivirine + tenofovir August 10, 2011 Gilead Sciences and
Janssen Therapeutics (formerly Tibotec)
Stribild elvitegravir + cobicistat + emtricitabine + tenofovir disoproxil August 27, 2012 Gilead Sciences
Triumeq abacavir + dolutegravir + lamivudine August 22, 2014 ViiV Healthcare
Evotaz atazanavir + cobicistat January 29, 2015 Bristol-Myers Squibb
Prezcobix darunavir + cobicistat January 29, 2015 Janssen Therapeutics
Dutrebis lamivudine + raltegravir February 6, 2015 Merck & Co.
Genvoya elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide November 5, 2015 Gilead Sciences

See also[edit]

References[edit]